Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588486 | 1.00 | APLNR (0.43) | APLNRNR1I2KMORIPK1FFAR2 | |
| SCHEMBL588484 | 1.00 | APLNR (0.43) | APLNRNR1I2KMORIPK1FFAR2 | |
| SCHEMBL22587369 | 0.84 | ESR1 (0.42) | — | |
| SCHEMBL22587371 | 0.84 | ESR1 (0.42) | — | |
| SCHEMBL588787 | 0.82 | ALDH1A1 (0.40) | MAPK1 | |
| SCHEMBL588789 | 0.82 | ALDH1A1 (0.40) | MAPK1 | |
| SCHEMBL28829748 | 0.82 | APLNR (0.47) | APLNRNR1I2CNR1CNR2HDAC6 | |
| SCHEMBL217839 | 0.80 | AGBL2 (0.31) | APLNRKCNH2 | |
| SCHEMBL217837 | 0.80 | AGBL2 (0.31) | APLNRKCNH2 | |
| SCHEMBL18040171 | 0.79 | GRIN2B (0.41) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569512-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8461185-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110003822-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | APLNR 175/4885NR1I2 598/4885KMO 1610/4885 |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | APLNR 175/4885NR1I2 598/4885KMO 1610/4885 |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | APLNR 192/4885NR1I2 579/4885KMO 1678/4885 |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | APLNR 192/4885NR1I2 579/4885KMO 1678/4885 |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | APLNR 175/4885NR1I2 598/4885KMO 1610/4885 |
| US-20110003822-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | APLNR 175/4885NR1I2 598/4885KMO 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.